BrainStorm appoints former FDA official Peter Pitts as Executive Chairman; Frenkel and Dagher depart

BRAINSTORM CELL THERAPEUTICS INC.

Peter Pitts, former FDA Associate Commissioner, appointed Executive Chairman and Chief Strategic Regulatory Officer on July 24, 2026.
Jacob Frenkel resigned as Chairman and director; transitions to Senior Advisor with 100,000 RSUs vesting over 6 months.
Ibrahim Dagher resigned as EVP and Chief Medical Officer on July 26, 2026; will consult for one year with equity vesting.
Pitts will lead NurOwn Phase 3b trial under first-ever FDA Special Protocol Assessment for an ALS therapeutic.
Pitts receives option for 900,000 shares vesting over 4 years; no salary or cash bonus.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.